企業プロフィール
Alnylam Pharmaceuticals, Inc. 株価・ニュース・カタリスト
- ティッカー:
- ALNY
- 取引所:
- NASDAQ
- セクター:
- Nucleic Acid Drugs
- 所在地:
- Cambridge, Massachusetts
株価パフォーマンス
224.60 USD (-1.77%)
終値
最終更新: 2026年8月17日
38.2B USD
時価総額
株価変動の要因
As of Aug 17, 2026, ALNY closed down 1.77% at $224.60. No new same-company headline was identified in the current news window.
企業概要
事業概要
Alnylam Pharmaceuticals is the pioneer of RNA interference therapeutics and one of the most important platform biotech companies in the market. Its approved medicines and pipeline programs focus on rare diseases and increasingly on more prevalent conditions.
所在地とセクター分類
Headquartered in Cambridge, Massachusetts and listed on NASDAQ, Alnylam is a U.S.-based biotech with a growing global commercial footprint. It sits squarely in the innovation-heavy side of biotechnology.
ビジネスモデルの特徴
The company combines product revenue, launch execution, and platform expansion with a deep RNAi pipeline. Investors watch adoption of approved medicines, label expansions, manufacturing scale, and the next wave of RNAi programs.
バイオ業界での位置付け
Alnylam occupies a top-tier position in platform biotech because it has already proved RNAi can work commercially. Compared with earlier-stage names, it has more durability, but it still reacts to regulatory and pipeline milestones.
今後のカタリスト
- Alnylam’s near-term catalysts are Amvuttra growth in ATTR-CM, Zilebesiran development, and broader RNAi adoption in cardiometabolic and rare disease. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
最近のニュース
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。